Adverse Effects Associated with SBRT in Patients With HCC

Opinion
Video

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
3 experts in this video
Related Content
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

Ariana Pelosci;Tim Cortese
April 11th 2025
Article

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD
December 4th 2023
Podcast

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

FDA Grants Fast Track Designation to Amezalpat Combination in HCC

FDA Grants Fast Track Designation to Amezalpat Combination in HCC

Tim Cortese
February 11th 2025
Article

Amezalpat plus atezolizumab and bevacizumab achieved a 6-month increase for OS compared with atezolizumab and bevacizumab alone in patients with HCC.

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Nivolumab Combo Earns Positive CHMP Opinion in Advanced Liver Cancer

Russ Conroy
February 1st 2025
Article

Findings from the CheckMate 9DW trial support the CHMP’s recommendation for approving nivolumab/ipilimumab for those with unresectable HCC.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

First-Line Serplulimab Plus HLX04 Shows Manageable Safety in Advanced HCC

Roman Fabbricatore
January 30th 2025
Article

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

TACE Plus Camrelizumab/Rivoceranib Extends PFS in Unresectable Liver Cancer

Russ Conroy
January 24th 2025
Article

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.